Skip to content

Study · In vitro (cells) · 2008

6 results

Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.

Chevrier L, Meunier AC, Cochaud S, Muller JM, Chadéneau C

International journal of oncology1 Nov 2008Cited by 15 (Europe PMC)

PMID18949372 (opens in a new tab)DOI10.3892/ijo_00000097 (opens in a new tab)PepBankPUB-18949372
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In human neuroblastoma cells, VIP reduced MYCN mRNA expression, especially in MYCN-amplified IMR-32 cells, with a maximal and transient decrease of approximately 50%.

    In plain wordsIn neuroblastoma cells, VIP lowered MYCN gene activity by about half for a short time, most in cells with extra MYCN copies.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseMYCN mRNA expression
    Study

    humann: not reported in source

    human neuroblastoma SH-SY5Y and IMR-32 cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    10(-6) M · few hoursAs given in this study (human).

    Measurements

    Maximal MYCN decrease
    ≈ 50%
    IMR-32 cells, VIP 10(-6) M

    Source sentences

    Summary
    The results indicated that VIP reduced MYCN mRNA and protein expression, especially in the MYCN-amplified IMR-32 cells, with a maximal and transient decrease by approximately 50% after few hours of treatment with VIP at 10(-6) M.
    1 context sentence
    Summary · context
    To determine whether VIP could modulate MYCN expression, we carried out real-time quantitative RT-PCR and Western immunoblot analyses in human neuroblastoma SH-SY5Y and IMR-32 cells.
  2. 02LabIn vitro (cells)Mechanism

    In human neuroblastoma cells, VIP reduced MYCN protein expression, especially in MYCN-amplified IMR-32 cells.

    In plain wordsIn neuroblastoma cells, VIP lowered MYCN protein, most in cells with extra MYCN copies.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseMYCN protein expression
    Study

    humann: not reported in source

    human neuroblastoma SH-SY5Y and IMR-32 cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    10(-6) M · few hoursAs given in this study (human).

    Source sentences

    Summary
    The results indicated that VIP reduced MYCN mRNA and protein expression, especially in the MYCN-amplified IMR-32 cells
    1 context sentence
    Summary · context
    To determine whether VIP could modulate MYCN expression, we carried out real-time quantitative RT-PCR and Western immunoblot analyses in human neuroblastoma SH-SY5Y and IMR-32 cells.
  3. 03LabIn vitro (cells)Mechanism

    In human neuroblastoma cells, VIP and retinoic acid (RA) showed complementary kinetics of MYCN mRNA reduction: VIP acted within hours and RA over days.

    In plain wordsIn neuroblastoma cells, VIP lowered MYCN within hours, while retinoic acid needed days, so their timing complements each other.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableTime course of MYCN decrease, VIP versus retinoic acid
    Study

    humann: not reported in source

    human neuroblastoma SH-SY5Y and IMR-32 cells
    Comparator
    Retinoic acid
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results indicated that VIP reduced MYCN mRNA and protein expression, especially in the MYCN-amplified IMR-32 cells, with a maximal and transient decrease by approximately 50% after few hours of treatment with VIP at 10(-6) M.
    2 context sentences
    Summary · context
    This effect was compared to that of RA at 10(-5) M, which induced a diminution of MYCN mRNA expression by approximately 25% after few days of treatment. This indicated that VIP and RA display complementary kinetics.
    Summary · context
    To determine whether VIP could modulate MYCN expression, we carried out real-time quantitative RT-PCR and Western immunoblot analyses in human neuroblastoma SH-SY5Y and IMR-32 cells.

Studies that did not test the peptide alone3

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In human neuroblastoma cells, cotreatment with VIP and retinoic acid had synergistic effects on regulation of MYCN protein expression.

    In plain wordsIn neuroblastoma cells, VIP plus retinoic acid together affected MYCN protein more than expected from each alone.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Direction not reportedMYCN protein with VIP plus retinoic acid
    Study

    humann: not reported in source

    human neuroblastoma SH-SY5Y and IMR-32 cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Cotreatments showed that VIP and RA had synergistic effects on regulation of expression of MYCN proteins.
    1 context sentence
    Summary · context
    To determine whether VIP could modulate MYCN expression, we carried out real-time quantitative RT-PCR and Western immunoblot analyses in human neuroblastoma SH-SY5Y and IMR-32 cells.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In human neuroblastoma cells, VIP and retinoic acid cotreatment regulated expression of the MYCN target gene SKP2.

    In plain wordsIn neuroblastoma cells, VIP plus retinoic acid together changed the activity of the MYCN-linked gene SKP2.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableSKP2 expression with VIP plus retinoic acid
    Study

    humann: not reported in source

    human neuroblastoma SH-SY5Y and IMR-32 cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    VIP and RA cotreatments regulated also expression of two MYCN target genes, SKP2 and TP53INP1.
    1 context sentence
    Summary · context
    To determine whether VIP could modulate MYCN expression, we carried out real-time quantitative RT-PCR and Western immunoblot analyses in human neuroblastoma SH-SY5Y and IMR-32 cells.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In human neuroblastoma cells, VIP and retinoic acid cotreatment regulated expression of the MYCN target gene TP53INP1.

    In plain wordsIn neuroblastoma cells, VIP plus retinoic acid together changed the activity of the MYCN-linked gene TP53INP1.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableTP53INP1 expression with VIP plus retinoic acid
    Study

    humann: not reported in source

    human neuroblastoma SH-SY5Y and IMR-32 cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    VIP and RA cotreatments regulated also expression of two MYCN target genes, SKP2 and TP53INP1.
    1 context sentence
    Summary · context
    To determine whether VIP could modulate MYCN expression, we carried out real-time quantitative RT-PCR and Western immunoblot analyses in human neuroblastoma SH-SY5Y and IMR-32 cells.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.